219 related articles for article (PubMed ID: 12445291)
1. Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes.
Melief CJ; Van Der Burg SH; Toes RE; Ossendorp F; Offringa R
Immunol Rev; 2002 Oct; 188():177-82. PubMed ID: 12445291
[TBL] [Abstract][Full Text] [Related]
2. The adjuvant effect of melanin is superior to incomplete Freund's adjuvant in subunit/peptide vaccines in mice.
Cuzzubbo S; Banissi C; Rouchon MS; Tran T; Tanchot C; Tartour E; Carpentier AF
Cancer Immunol Immunother; 2020 Dec; 69(12):2501-2512. PubMed ID: 32561966
[TBL] [Abstract][Full Text] [Related]
3. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination.
Galea-Lauri J; Darling D; Mufti G; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2002 Aug; 51(6):299-310. PubMed ID: 12111118
[TBL] [Abstract][Full Text] [Related]
4. Direct Loading of iTEP-Delivered CTL Epitope onto MHC Class I Complexes on the Dendritic Cell Surface.
Dong S; Wang P; Zhao P; Chen M
Mol Pharm; 2017 Oct; 14(10):3312-3321. PubMed ID: 28789525
[TBL] [Abstract][Full Text] [Related]
5. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy.
Knutson KL; Disis ML
Cancer Immunol Immunother; 2005 Aug; 54(8):721-8. PubMed ID: 16010587
[TBL] [Abstract][Full Text] [Related]
6. Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides.
Fujiki F; Tsuboi A; Morimoto S; Hashimoto N; Inatome M; Nakajima H; Nakata J; Nishida S; Hasegawa K; Hosen N; Oka Y; Oji Y; Sogo S; Sugiyama H
Cancer Immunol Immunother; 2021 Jan; 70(1):253-263. PubMed ID: 32696072
[TBL] [Abstract][Full Text] [Related]
7. Enhanced immune response induced by P5 HER2/neu-derived peptide-pulsed dendritic cells as a preventive cancer vaccine.
Gholizadeh Z; Tavakkol-Afshari J; Nikpoor AR; Jalali SA; Jaafari MR
J Cell Mol Med; 2018 Jan; 22(1):558-567. PubMed ID: 28944998
[TBL] [Abstract][Full Text] [Related]
8. Generation of robust cytotoxic T lymphocytes against prostate specific antigen by transduction of dendritic cells using protein and recombinant adeno-associated virus.
Mahadevan M; Liu Y; You C; Luo R; You H; Mehta JL; Hermonat PL
Cancer Immunol Immunother; 2007 Oct; 56(10):1615-24. PubMed ID: 17356843
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors.
Bae J; Hideshima T; Tai YT; Song Y; Richardson P; Raje N; Munshi NC; Anderson KC
Leukemia; 2018 Sep; 32(9):1932-1947. PubMed ID: 29487385
[TBL] [Abstract][Full Text] [Related]
10. Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28.
Rosenblatt J; Wu Z; Vasir B; Zarwan C; Stone R; Mills H; Friedman T; Konstantinopoulos PA; Spentzos D; Ghebremichael M; Stevenson K; Neuberg D; Levine JD; Joyce R; Tzachanis D; Boussiotis V; Kufe D; Avigan D
J Immunother; 2010; 33(2):155-66. PubMed ID: 20145548
[TBL] [Abstract][Full Text] [Related]
11. Harnessing neoantigen specific CD4 T cells for cancer immunotherapy.
Brightman SE; Naradikian MS; Miller AM; Schoenberger SP
J Leukoc Biol; 2020 Apr; 107(4):625-633. PubMed ID: 32170883
[TBL] [Abstract][Full Text] [Related]
12. Current State of Dendritic Cell-Based Immunotherapy: Opportunities for
Huber A; Dammeijer F; Aerts JGJV; Vroman H
Front Immunol; 2018; 9():2804. PubMed ID: 30559743
[TBL] [Abstract][Full Text] [Related]
13. Tumor antigen presentation: changing the rules.
Armstrong TD; Pulaski BA; Ostrand-Rosenberg S
Cancer Immunol Immunother; 1998 Apr; 46(2):70-4. PubMed ID: 9558001
[TBL] [Abstract][Full Text] [Related]
14. Killer dendritic cells and their potential for cancer immunotherapy.
Larmonier N; Fraszczak J; Lakomy D; Bonnotte B; Katsanis E
Cancer Immunol Immunother; 2010 Jan; 59(1):1-11. PubMed ID: 19618185
[TBL] [Abstract][Full Text] [Related]
15. Impact of the tumor microenvironment on host infiltrating cells and the efficacy of flt3-ligand combination immunotherapy evaluated in a treatment model of mouse prostate cancer.
Ciavarra RP; Brown RR; Holterman DA; Garrett M; Glass WF; Wright GL; Schellhammer PF; Somers KD
Cancer Immunol Immunother; 2003 Sep; 52(9):535-45. PubMed ID: 14627125
[TBL] [Abstract][Full Text] [Related]
16. Vaccines targeting helper T cells for cancer immunotherapy.
Melssen M; Slingluff CL
Curr Opin Immunol; 2017 Aug; 47():85-92. PubMed ID: 28755541
[TBL] [Abstract][Full Text] [Related]
17. Utilizing murine dendritic cell line DC2.4 to evaluate the immunogenicity of subunit vaccines
Lu L; Kong WY; Zhang J; Firdaus F; Wells JW; Stephenson RJ; Toth I; Skwarczynski M; Cruz JLG
Front Immunol; 2024; 15():1298721. PubMed ID: 38469294
[TBL] [Abstract][Full Text] [Related]
18. CD4
Lei X; de Groot DC; Welters MJP; de Wit T; Schrama E; van Eenennaam H; Santegoets SJ; Oosenbrug T; van der Veen A; Vos JL; Zuur CL; de Miranda NFCC; Jacobs H; van der Burg SH; Borst J; Xiao Y
Cell Mol Immunol; 2024 Apr; 21(4):374-392. PubMed ID: 38383773
[TBL] [Abstract][Full Text] [Related]
19. DC-based vaccine loaded with acid-eluted peptides in acute myeloid leukemia: the importance of choosing the best elution method.
Delluc S; Tourneur L; Fradelizi D; Rubio MT; Marchiol-Fournigault C; Chiocchia G; Buzyn A
Cancer Immunol Immunother; 2007 Jan; 56(1):1-12. PubMed ID: 16676183
[TBL] [Abstract][Full Text] [Related]
20. Function and dysfunction of CD4(+) T cells in the immune response to melanoma.
Fischer WH; thor Straten P; Terheyden P; Becker JC
Cancer Immunol Immunother; 1999 Oct; 48(7):363-70. PubMed ID: 10501848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
